Dry blending and direct compression of oclacitinib maleate for oral veterinary tablets begins with particle-size control on the as-received crystalline active. If the material does not pass through a 250 µm sieve by manual screening, a conical mill or spiral jet mill is used to reduce the D90 to a band of 30–75 µm; published oclacitinib maleate-specific particle-size distribution data are limited, and the target is selected to maintain a low-dosage blend with sufficient surface area for content uniformity under USP <905>. A binary pre-blend of the milled API with microcrystalline cellulose and lactose monohydrate is prepared in a bin blender with an intensifier bar, and croscarmellose sodium is added as a disintegrant before final lubrication with magnesium stearate at 0.5% w/w to 1.0% w/w. The lubricant blending time is limited to 5 min at 25 rpm or less on a 25 L bin blender because prolonged bed movement can produce a hydrophobic film on the carrier particles and shift disintegration above the 15 min limit in USP <701>. Compression is performed on a rotary tablet press fitted with 6 mm round multi-tip tooling and a precompression station at 6–10 kN; main compression forces from 14–22 kN produce tablets with a crushing strength of 50–80 N, a friability below 1.0% under USP <1216>, and a disintegration time below 15 min in pH 1.2 or pH 4.5 media. Immediate-release dissolution is evaluated by USP <711> Apparatus 2 at 50 rpm with a sampling matrix at 15, 30, and 45 min; a conventional acceptance criterion of Q ≥ 80% at 30 min is applied for film-coated tablets. Commercial veterinary reference strengths in the United States include 3.6 mg, 5.4 mg, and 16 mg of oclacitinib per tablet as the maleate salt, and the API mass per tablet is adjusted by the counterion ratio to meet label claim. Aqueous film coating with hypromellose or polyvinyl alcohol-based dispersions is applied in a perforated pan coater at inlet air temperature 60–75 °C, bed temperature 40–48 °C, and pan speed 6–12 rpm; the coating weight gain is controlled to 2.0%–3.5% by gravimetric monitoring because lower weight gain increases edge chipping, while higher weight gain can delay dissolution beyond the immediate-release window.

Compression runs above 100,000 tablets/h may generate electrostatic adhesion of the low-dose blend to the die walls, and the resulting weight variation is detected by in-process force feedback; when the relative standard deviation of compression force exceeds 5% over 30 min, the press is stopped for punch and die cleaning. Tablet friability is measured using a USP <1216> drum at 25 rpm for 100 revolutions; a friability above 0.8% indicates poor compaction and predicts edge chipping during film coating. Dissolution failures are investigated by comparing disintegration time and tablet hardness profile, because over-compression above 80 N can close the capillary channels needed for medium penetration. The film-coating process uses a spray rate of 5–10 mL/min per gun and atomising air pressure of 1.0–1.5 bar; if the spray rate is too high relative to the pan exhaust capacity, tablet core moisture can exceed 2.0% and reduce chemical stability. The coated tablets are packaged in high-density polyethylene bottles with heat-sealed induction liners and desiccant; storage is controlled below 30 °C because the commercial oral tablet label specifies controlled room temperature and protection from moisture. Stability testing follows ICH Q1A(R2) at 25 °C/60% RH and 40 °C/75% RH, with assay, related substances, dissolution, water content, and film adhesion as shelf-life attributes.

What Capsule Filling Parameters Govern Content Uniformity for Low-Dose Oclacitinib Maleate Blends?

A low-dose capsule product requires geometric dilution of oclacitinib maleate before encapsulation because direct filling of a crystalline drug with a large excipient carrier can produce segregation during hopper vibration. The API is first triturated with a portion of lactose monohydrate in a mortar or high-shear mixer at a ratio of 1:1 to 1:5, then passed through a 500 µm sieve and combined with the remaining lactose, microcrystalline cellulose, and a glidant such as colloidal silicon dioxide at 0.5% w/w to 1.0% w/w. The final blend is sampled at 10 locations in the blender and assayed by high-performance liquid chromatography with ultraviolet detection; acceptance is based on mean assay 90.0%–110.0% and relative standard deviation ≤ 5.0% before capsule filling. Hard gelatin capsules in size 3 or 4 are filled on a dosator or tamping-pin machine at a target fill weight of 80–150 mg, and the fill weight is monitored every 15 min with a weight sorter; tamping-pin compression forces of 10–30 N are adjusted to minimise powder bed density variation without forming a plug that retards shell dissolution. Room conditions are held at 20–25 °C and 40–50% relative humidity because hard gelatin becomes brittle below 40% relative humidity and can crosslink or become tacky above 60% relative humidity. Hydroxypropyl methylcellulose capsules are preferred when the formulation contains trace aldehydes or when low-moisture protection is required; dissolution testing is performed by USP <711> Apparatus 1 at 100 rpm in 0.1 M hydrochloric acid or pH 4.5 acetate buffer, with a Q ≥ 80% at 30 min as a reasonable immediate-release acceptance limit. Capsule content uniformity follows USP <905>, but the statistical sampling requires all individual units within 85.0%–115.0% of label claim and an acceptance value ≤ 15 for the first 10 units. Filled capsules are inspected for shell integrity, weight, and closure; a manual rejection rate above 0.2% typically triggers adjustment of the capsule feed vibratory amplitude or vacuum separation pressure. The final package is heat-sealed in aluminium/aluminium blisters with desiccant when accelerated stability at 40 °C/75% RH under ICH Q1A(R2) shows moisture ingress or capsule softening.

Segregation in the capsule hopper is monitored by sampling at the beginning, middle, and end of the encapsulation run; if the mean assay deviates by more than 3% from the initial blend value, the hopper load is reduced and the fill speed is lowered. The filled capsule weight distribution is measured by a checkweigher at 50–70 capsules/min; individual weights outside ±5% of the target are rejected, and a sustained rejection rate above 0.2% triggers a full line stop. Dissolution failures for capsules are often caused by gelatin crosslinking or by over-compression of the powder plug; the dissolution medium may include pepsin or pancreatic enzyme under USP <711> for hard gelatin capsules when crosslinking is suspected, but enzyme addition is not routinely justified for oclacitinib maleate unless validated. The capsule product is packaged in cold-form aluminium/aluminium blisters to limit moisture transmission below 0.5 g/m²/day; the blister cavity is filled under nitrogen if oxidative degradation is detected in the stress stability screen. An ongoing stability batch is stored at 25 °C/60% RH and 40 °C/75% RH according to ICH Q1A(R2), and the capsule appearance is inspected for shell cracking, warping, or leakage after each time point.

Wet granulation of oclacitinib maleate is used when oral dosage forms require dose titration in multi-dog households or when direct compression blends cannot achieve the required bulk density for sachet filling. The process starts with a dry pre-mix of the API, lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium in a high-shear granulator; purified water or a 2% w/w povidone K30 binder solution is added at an impeller speed of 200–400 rpm and a chopper speed of 1,500–3,000 rpm. Granulation endpoint is determined by impeller torque or power consumption, and published oclacitinib maleate-specific endpoint data are limited; a torque rise of 15%–25% above dry mix baseline is typically used as a provisional cutoff, with subsequent confirmation by sieve analysis. The wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer at inlet air temperature 55–70 °C until loss on drying is 1.0%–2.5%. Dried granules are sized through a 800 µm sieve, and the fines fraction below 75 µm is limited to ≤ 10% of total granule mass to avoid sachet dusting and segregation. The granule bulk density is measured by USP <616>; a target bulk density of 0.45–0.65 g/mL and tapped density of 0.55–0.75 g/mL are selected to ensure consistent fill weight on a stick-pack machine. Sachet fill weight is set between 1.0 g and 5.0 g depending on the labelled oclacitinib concentration, and the fill line is operated with auger filling or volumetric cup filling under nitrogen purge when static charge builds up. Palatability in granules for veterinary patients is a critical process output; published palatability data for oclacitinib maleate granules are limited, but a coated granule or spray-dried flavor system is often required because the API has a bitter aftertaste that can reduce voluntary intake. Dissolution testing of granules is executed by USP <711> Apparatus 2 on a sample containing the full dose, with a Q ≥ 75% at 30 min in pH 4.5 acetate buffer as a provisional acceptance criterion. Stability of the granule-filled sachets is evaluated at 25 °C/60% RH and 40 °C/75% RH according to ICH Q1A(R2), with assay, impurity, moisture, and dissolution as the main shelf-life attributes.

Granule flow is characterised by Carr index and Hausner ratio under USP <1174>. A Hausner ratio below 1.20 is targeted for sachet filling; ratios above 1.35 indicate poor flow and require increased glidant or granule spheronisation. Batch-to-batch variation in granule moisture above ±0.5% is a common failure mode on fluid-bed drying, and the process is corrected by adjusting inlet air dew point or final drying time. For veterinary palatability, fluid-bed coating of granules with a taste-masking polymer may be required; the coating level of 3.0%–5.0% w/w is controlled gravimetrically and the coated granules are re-screened through 1.0 mm to remove agglomerates. Dissolution of coated granules is tested with the same apparatus but after a 5 min acid pre-incubation to mimic gastric residence; release below 70% at 30 min indicates overcoating or hydrophobic granule surfaces. The sachet material is a polyester/aluminium/polyethylene laminate with a moisture vapour transmission rate below 0.5 g/m²/day; the filled sachets are placed in outer cartons and stored below 25 °C unless long-term data support 30 °C. Each granule batch is compared against the previous three batches for particle-size distribution, bulk density, and dissolution to detect process drift.

Terminal Sterilisation Trade-Offs in Aqueous Injectable Formulations

Oclacitinib maleate as an injectable active requires a sterile aqueous vehicle, but terminal steam sterilisation can hydrolyse the maleate counterion or promote dimer formation if the pH and buffer species are not selected against forced-degradation data. The formulation is prepared with Water for Injection and a buffer system screened over a pH range of 3.0–5.0 because the free base has pH-dependent aqueous solubility; published oclacitinib maleate pH-solubility profiles are limited, and a preformulation study with acetate or citrate buffers at 10–50 mM is required to define the pH of maximum solubility and minimum hydrolysis. The bulk solution is filtered through a 0.22 µm polyvinylidene fluoride or polyethersulfone filter at a differential pressure below 2.0 bar, then filled into Type I borosilicate glass vials under ISO 14644-1 Class 5 laminar airflow. If terminal sterilisation is selected, the filled sealed vials are autoclaved at 121 °C for 15 min or an equivalent F0 ≥ 8 min; however, this is conditionally acceptable only if forced-degradation and process validation show no more than 0.5% assay loss and no unidentified impurity above the ICH Q3B identification threshold. When heat degradation exceeds that boundary, aseptic processing is substituted and the entire sequence from filtration through filling occurs without terminal heat treatment; this decision is driven by stability-indicating high-performance liquid chromatographic profiling under ICH Q1A(R2) stress conditions. The sterile product is tested for appearance, pH, osmolality, particulate matter, sterility, and bacterial endotoxins; the table below lists the corresponding method designations used as the release matrix. Endotoxin limits are calculated according to USP <85> using the maximum dose and the rabbit or kinetic chromogenic limulus amebocyte lysate method; for a 10 mg injectable dose, a common veterinary parenteral limit is ≤ 0.5 EU/mg, but the actual limit must be derived from the labelled dose. Subvisible particulate monitoring by light obscuration follows USP <788> Method 1, with acceptance limits for ≥ 10 µm and ≥ 25 µm particle sizes; visible inspection is performed after filling and again after terminal sterilisation or quarantine. The rubber stopper and vial glass are assessed for extractables and leachables under USP <1663> because the acidic formulation may extract metal ions from borosilicate or organic extractables from elastomeric closures. Headspace oxygen is controlled below 2% by nitrogen overlay if oxidative degradation is identified in forced-degradation studies; if oxygen sensitivity is absent, air headspace is acceptable but may reduce shelf-life. The injectable solution is stored at 2–8 °C if stability data do not support room-temperature storage, and the label specifies the in-use hold time after first stopper puncture based on microbial challenge under USP <51> for multi-dose configurations.

Process analytical technology can be deployed on the filling line with near-infrared or ultraviolet absorbance sensors to verify the active concentration in the bulk solution before filtration; however, oclacitinib maleate injection is not widely commercialised, so published vendor-specific process analytical technology data are limited. If the injectable is intended for multi-dose vials, the container closure integrity is challenged by dye ingress testing under USP <1207> and microbial immersion; vacuum decay or high-voltage leak detection is used after capping to detect seal defects below 5 µm equivalent leak diameter. The final aqueous solution is not suitable for intravenous use without osmolality adjustment; if the formulation is hyperosmotic, the route may be restricted to subcutaneous or intramuscular administration, and the label must state the route and rate. Particulate matter failures after terminal sterilisation are often traced to glass delamination in acidic solutions; the container glass is evaluated for surface hydrolytic resistance under USP <660> or Ph. Eur. 3.2.1. The product is protected from light because photodegradation of the nitrogen-containing heteroaromatic core can generate N-oxide or sulfone-related impurities.

When Lyophilised Oclacitinib Maleate Is Required for Cold-Chain-Independent Distribution

Lyophilisation is evaluated when aqueous oclacitinib maleate injectable solutions show insufficient chemical stability at 2–8 °C or when distribution to remote veterinary clinics requires storage below 25 °C without continuous refrigeration. The pre-lyophilisation solution is filled into Type I glass vials and partially stoppered; a formulation matrix of mannitol, glycine, or trehalose at 2.0%–5.0% w/w is screened because these bulking agents provide a mechanically stable cake and may protect against freeze-induced aggregation. Thermal characterisation of the frozen formulation is performed by differential scanning calorimetry and freeze-drying microscopy to determine the glass transition of the maximally freeze-concentrated solution and the collapse temperature; published oclacitinib maleate lyo data are limited, but mannitol or trehalose systems typically exhibit a critical collapse temperature between -32 °C and -25 °C, so shelf temperatures are held below that boundary during primary drying. A conservative cycle uses freezing at -40 °C to -45 °C for 2–4 h, primary drying at shelf temperature -30 °C to -20 °C with a chamber pressure of 80–150 mTorr, and secondary drying at 40 °C for 4–8 h until the cake temperature approaches the shelf set point. The residual moisture of the freeze-dried cake is determined by coulometric Karl Fischer titration under USP <921> Method 1c or Ph. Eur. 2.5.32 and is controlled to ≤ 1.0% water; higher residual moisture can reduce the glass transition temperature of the amorphous phase and permit cake shrinkage or potency loss. The final container is sealed under vacuum or nitrogen, and the reconstitution time is recorded by adding the specified volume of Water for Injection and swirling; a typical acceptance criterion for a 10 mL vial is complete dissolution within 2 min, with no visible particles and no foam. The reconstituted solution is tested for pH, osmolality, particulate matter by USP <788>, and sterility by USP <71>; if the vial is reconstituted in a clinical setting, the in-use stability window is established by analytical testing at 25 °C and 2–8 °C over 24 h to 48 h. Lyophilised product is placed on long-term stability at 25 °C/60% RH and accelerated stability at 40 °C/75% RH under ICH Q1A(R2), and the cake is inspected for meltback, collapse, or elevated headspace oxygen exceeding 2%. If the formulation contains mannitol, annealing at -10 °C to -20 °C during the freezing ramp may be used to crystallise the bulking agent and reduce vial breakage during production; the annealed cycle is validated by differential thermal analysis to confirm complete mannitol crystallisation. The lyophilised format is considered only when the aqueous formulation fails the assigned shelf-life or when the target import market has a limited cold chain, because freeze-drying adds process time and requires a fully stoppered vial under moisture-impermeable sealing.

Freeze-drying equipment qualification includes shelf temperature mapping with 12 thermocouples and pressure distribution testing across the lyophiliser; a shelf temperature variation above ±1 °C during primary drying can cause edge vials to collapse while centre vials remain under-dried. The vial heat transfer coefficient is influenced by the vial bottom concavity and the tray position; direct contact trays reduce heat transfer variability compared with wire trays. After lyophilisation, the vials are unloaded under Grade A conditions and crimped with an aluminium overseal; the seal integrity is verified by vacuum decay or dye intrusion after capping. If the product is stored at room temperature, the glass transition temperature of the dried cake should be at least 20 °C above the intended storage temperature; for a 25 °C storage condition, a Tg above 45 °C is desirable, though the actual Tg depends on the residual moisture and the amorphous excipient fraction. The reconstituted injection is administered by the intramuscular or subcutaneous route, and the final label specifies the reconstitution diluent, the final volume, and the hold time; no preservative is included in single-dose vials.

Oral Suspension Compounding for Individualised Veterinary Dose Titration

Compounded oral suspensions of oclacitinib maleate are prepared when the commercial tablet strengths cannot be divided safely for small or juvenile veterinary patients and when a liquid dosage enables fine dose adjustment. The compounding process uses a mortar and pestle or electronic mortar and pestle to reduce the API particle size; the active is wetted with a small volume of a suspending vehicle composed of purified water, glycerin, and a suspending agent such as methylcellulose or xanthan gum. The final concentration is typically between 1 mg/mL and 10 mg/mL of oclacitinib as the maleate salt, depending on the calibrated dosing syringe and the animal body weight; the concentration is confirmed by an analytical method before release because standard concentration checks by volume are not sufficient for a low-dose veterinary suspension. A preservative is included for multi-dose containers, and the antimicrobial effectiveness is evaluated by USP <51>; if the formulation is preserved, the beyond-use date is assigned according to USP <795> for preserved aqueous oral liquids, typically not exceeding 35 days under refrigeration at 2–8 °C. The suspension is packaged in amber glass or polyethylene terephthalate bottles with child-resistant closures, and patients are instructed to shake immediately before use because oclacitinib maleate may settle over time. pH is adjusted to 3.0–5.0 with citrate buffer to minimise hydrolysis and improve chemical stability; published stability data for oclacitinib maleate oral suspension are limited, so a stability-indicating high-performance liquid chromatographic study is performed over the intended beyond-use date before a specific storage recommendation is made. Viscosity is measured with a rotational viscometer at 25 °C, and a target viscosity of 50–200 mPa·s is used to balance pourability and suspension uniformity; thixotropic vehicles are avoided because syringe withdrawal can vary with shear rate. Dose accuracy is tested by withdrawing the prescribed volume with oral syringes of 1 mL, 3 mL, and 5 mL capacity, and the delivered dose at each graduation is verified by weight or high-performance liquid chromatography. The suspension is not autoclaved; it is prepared under non-sterile conditions but protected from light and stored in a refrigerator, since oclacitinib maleate is not approved for ophthalmic or parenteral use in this form. Chemical stability is monitored for assay, pH, appearance, and preservative concentration at day 0, day 7, day 14, day 28, and day 35; any loss exceeding 5% from initial assay truncates the beyond-use date to the previous stable time point.

The compounded suspension is not a substitute for a registered commercial tablet in jurisdictions where the tablet is available; it is used only under veterinary prescription and when the authorised product cannot meet the patient's weight-adjusted dose. The compounding record includes the API lot number, the beyond-use date, the storage instructions, and the analytical verification result; omissions in these records are considered a deviation under USP <795>. The syringeability of the suspension is checked by drawing the dose into a syringe at 2–8 °C and at room temperature, because methylcellulose solutions can gel upon heating and xanthan gum can lose viscosity after freeze-thaw cycles. The suspension should not be frozen; freeze-thaw can cause particle agglomeration and phase separation, which alters the delivered dose. Chemical instability is commonly seen as an increase in hydrolytic degradation products and a downward pH drift over the beyond-use date; if pH drifts by more than 0.5 units, the batch is discarded. The formulation is prepared under low-light conditions, and the final label states “shake well before use” and “protect from light.”